Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series B | Alive

Total Raised


Last Raised

$36.5M | 9 mos ago

About Spotlight Therapeutics

Spotlight Therapeutics develops biologics targeted to specific cell populations in gene editing.

Spotlight Therapeutics Headquarters Location

3953 Point Eden Way

Hayward, California, 94545,

United States

(510) 543-0700

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Spotlight Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Spotlight Therapeutics in 1 CB Insights research brief, most recently on Nov 19, 2019.

Expert Collections containing Spotlight Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Spotlight Therapeutics is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Spotlight Therapeutics Patents

Spotlight Therapeutics has filed 3 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • DNA
  • Genetic engineering
patents chart

Application Date

Grant Date


Related Topics



Molecular biology, Genetics, Biotechnology, DNA, Genetic engineering


Application Date


Grant Date


Related Topics

Molecular biology, Genetics, Biotechnology, DNA, Genetic engineering



Latest Spotlight Therapeutics News

Spotlight Therapeutics Appoints Nallakkan Arvindan, Ph.D., MBA, as EVP and Chief Technology Officer

Sep 12, 2022

Dr. Arvindan Brings Two Decades of Broad Industry Expertise in Technology Development and Operations Download Nallakkan Arvindan, Ph.D., MBA (Photo: Business Wire) September 12, 2022 07:30 AM Eastern Daylight Time SAN FRANCISCO--( BUSINESS WIRE )--Spotlight Therapeutics, Inc. (“Spotlight”), a biotechnology company applying new insights to develop cell-targeted in vivo CRISPR gene editing biologics, today announced the appointment of Nallakkan Arvindan, Ph.D., MBA as Executive Vice President and Chief Technology Officer. Dr. Arvindan brings two decades of industry experience, most recently as Senior Vice President, Strategic Technology Operations and member of the executive team at Five Prime Therapeutics, Inc. until its acquisition by Amgen. "We are delighted to welcome Arvind to Spotlight’s leadership team. His demonstrated success in driving operational improvements and fostering company evolution will be invaluable as we continue to advance our TAGE (Targeted Active Gene Editors) platform and pipeline," said Mary Haak-Frendscho, Ph.D., President and Chief Executive Officer of Spotlight. "Arvind has deep experience in biologics and will play a key role in helping Spotlight bring a new class of CRISPR ribonucleoprotein therapeutics to patients.” During Dr. Arvindan’s Five Prime tenure, he helped develop their novel, fully automated, biologics discovery and development platform to support a first-in-class clinical stage Immuno-Oncology pipeline. He holds an M.B.A. from the University of California, Berkeley, and a Ph.D. in Chemical Engineering and Nanotechnology from the University of Washington, Seattle. “I am thrilled to join Spotlight to help lead the company in developing a first-in-class, modular biologics platform for a new generation of cell-targeted in vivo CRISPR gene editing therapeutics,” said Dr. Arvindan. “Spotlight’s innovative biologics approach provides an unparalleled opportunity to deliver transformative medicines.” “Spotlight is at an exciting stage of growth, and Arvind’s broad expertise and industry knowledge makes him an outstanding addition helping to accelerate our momentum towards the clinic,” said Craig Gordon, M.D., Spotlight board member, Founder, CEO, and CIO of GordonMD™ Global Investments. About Spotlight Therapeutics Established in 2018, Spotlight Therapeutics is a privately held biotechnology company advancing a pipeline of cell-targeted in vivo CRISPR gene editing therapies. Spotlight's proprietary technology platform TAGE (Targeted Active Gene Editors) is a new class of biologics, CRISPR effectors engineered for direct delivery in vivo, to achieve cell-selective therapeutic genome editing. Spotlight's pipeline is advancing its modular programmable CRISPR effectors towards clinical studies in immuno-oncology, ophthalmic diseases and hemoglobinopathies. The company is headquartered in Hayward, California. For more information, please visit . Contacts

Spotlight Therapeutics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Spotlight Therapeutics Rank

  • When was Spotlight Therapeutics founded?

    Spotlight Therapeutics was founded in 2018.

  • Where is Spotlight Therapeutics's headquarters?

    Spotlight Therapeutics's headquarters is located at 3953 Point Eden Way, Hayward.

  • What is Spotlight Therapeutics's latest funding round?

    Spotlight Therapeutics's latest funding round is Series B.

  • How much did Spotlight Therapeutics raise?

    Spotlight Therapeutics raised a total of $65.86M.

  • Who are the investors of Spotlight Therapeutics?

    Investors of Spotlight Therapeutics include Google Ventures, EPIQ Capital Group, GordonMD Global Investments, Emerson Collective and Magnetic Ventures.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.